참고문헌
- Abdullah S, Mustafa K, Gurhan B, et al (2013). CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. Asian Pac J Cancer Prev, 14, 4289-94. https://doi.org/10.7314/APJCP.2013.14.7.4289
- Buyru N, Tigli H, Duranyildiz D, et al (2006). Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients. Clin Chem Lab Med, 44, 538-41.
- Bates SE (1991). Clinical applications of serum tumor markers. Ann Intern Med, 115, 623-38. https://doi.org/10.7326/0003-4819-115-8-623
- Chen SW, Liang JA, Hung YC, et al (2008). Clinical implications of elevated pretreatment carcinoembryonic antigen in patients with advanced squamous cell carcinoma of the uterine cervix. Tumour Biol, 29, 255-61. https://doi.org/10.1159/000152943
- Carpelan-Holmstro M, Louhimo J, Stenman UH, et al (2002). CEA, CA19-9 and CA72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res, 22, 2311-6.
- Choi SR, Jang JS, Lee JH, et al (2006). Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci, 51, 2081-6. https://doi.org/10.1007/s10620-006-9166-5
- Edge SB, Compton CC (2010). The american joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4. https://doi.org/10.1245/s10434-010-0985-4
- Fernandes LL, Martins LC, Nagashima CA, et al (2007). CA72-4 antigen levels in serum and peritoneal washing in gastric cancer. Correlation with morphological aspects of neoplasia. Arq Gastroenterol, 44, 235-9. https://doi.org/10.1590/S0004-28032007000300011
- Feng JF, Huang Y, Chen QX (2013). Prognostic value of preoperative serum CA 242 in esophageal squamous cell carcinoma cases. Asian Pac J Cancer Prev, 14, 1803-6. https://doi.org/10.7314/APJCP.2013.14.3.1803
- Grinbaum R, Nissan A, Beglaibter N, et al (2006). The prognostic value of CA 19-9 in the preoperative work-up of pancreatic cancer patients. Harefuah, 145, 793-4, 863.
- Goral V, Yesilbagdan H, Kaplan A, et al (2007). Evaluation of CA 72-4 as a new tumor marker in patients with gastric cancer. Hepatogastroenterology, 54, 1272-5.
- Gao ZL, Zhang C, Du GY, et al (2007). Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology, 54, 1591-5.
- Gupta G, Sharma R, Chattopadhyay TK, et al (2007). Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer, 120, 1739-47. https://doi.org/10.1002/ijc.22463
- Gao ZL, Zhang C, Du GY, et al (2007). Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology, 54, 1591-5.
- Gwak HK, Lee JH, Park SG (2014). Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer. Asian Pac J Cancer Prev, 15, 4933-8. https://doi.org/10.7314/APJCP.2014.15.12.4933
- Jing JX, Xu XQ, Du LL, et al (2013). Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer. Int J Biol Markers, 28, 192-200. https://doi.org/10.5301/jbm.5000023
- Kosugi S, Nishimaki T, Kanda T, et al (2004). Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg, 28, 680-5.
- Kosugi S, Nishimaki T, Kanda T, et al (2004). Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg, 28, 680-5.
- Lin Y, Totsuka Y, He Y, et al (2013). Epidemiology of esophageal cancer in Japan and China. J Epidemiol, 23, 233-42. https://doi.org/10.2188/jea.JE20120162
- Molina R, Auge JM, Filella X, et al (2005). Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res, 25, 1773-8.
- Marrelli D, Roviello F, De Stefano A, et al (2004). Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg, 198, 51-8. https://doi.org/10.1016/j.jamcollsurg.2003.08.013
- Marrelli D, Roviello F, De Stefno A, et al (1999). Prognostic significance of CEA, CA19-9 and CA72-4 preoperative serum levels in gastric carcinoma. Oncology, 57, 55-62. https://doi.org/10.1159/000012001
- Mandorwski S, Lour Lourenco LG, Forones NM, et al (2002). CA72-4 and CEA in serum and peritoneal washing in gastric cancer. Arq Gastroenterol, 39, 17-21. https://doi.org/10.1590/S0004-28032002000100004
- Mao YS, Zhang DC, Zhao XH, et al (2003). Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer. Zhonghua Zhong Liu Za Zhi, 25, 457-60.
- Nishimaki T, Suuki T, Kanda T, et al (1999). Extended radical esophagectomy for superficially invasive carcinoma of the esophagus. Surgery, 125, 142-7. https://doi.org/10.1016/S0039-6060(99)70257-6
- Nishimaki T, Tanaka O, Ando N, et al (1999). Evaluation of the accuracy of preoperative staging in thoracic esophageal cancer. Ann Thorac Surg, 68, 2059-64. https://doi.org/10.1016/S0003-4975(99)01171-6
- Nakamura T, Ide H, Eguchi R, et al (1998). CYFRA21-1 as a tumor marker for squamous cell carcinoma. Esophagus, 11, 35-9.
- Oremek GM, Sapoutzis N, Lorenz M, et al (2003). Phospholipids, tumour marker and beta-CrossLaps in diagnosis of gastric carcinoma. Anticancer Res, 23, 859-63.
- Patriti A, Graziosi L, Baffa N, et al (2007). Postoperative followup of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/TC. Ann Ital Chir, 78, 481-5.
- Park YP, Choi SC, Kim JH, et al (2007). Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer, 120, 813-20. https://doi.org/10.1002/ijc.22369
- Schneider J, Schulze G (2003). Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res, 23, 5089-93.
- Safi F, Kuhns V, Beger HG, et al (1995). Comparison of CA72-4, CA19-9 and CEA in the diagnosis and monitoring of gastric cancer. Int J Biol Markers, 10, 100-6.
- Shimada H, Nabeya Y, Okazumi S, et al (2003). Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery, 133, 486-94. https://doi.org/10.1067/msy.2003.139
- Takemura M, Osugi H, Takada N, et al (2004). The prognostic factors after radical esophagectomy for esophageal cancer with sensitive preoperative CEA. Hepatogastroenterol, 51, 159-62.
- Takahashi Y, Takeuchi T, Sakamoto J, et al (2003). The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer, 6, 142-5. https://doi.org/10.1007/s10120-003-0240-9
- Tian SB, Yu JC, Kang WM, et al (2014). Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev, 15, 6295-300. https://doi.org/10.7314/APJCP.2014.15.15.6295
- Ucar E, Semerci E, Ustun H, et al (2008). Prognostic value of preoperative CEA, CA19-9, CA72-4, and AFP levels in gastric cancer. Adv Ther, 25, 1075-84. https://doi.org/10.1007/s12325-008-0100-4
- Wu H, Cheng NS, Zhang YG, et al (2007). Improved early diagnosis of cystadenocarcinoma of the pancreas. Hepatobiliary Pancreat Dis Int, 6, 87-91.
- Wang DC, Wang LD, Zheng S, et al (2005). The application of surface-enhanced laser desorption/ionization-time of flightmass spectrometry in diagnosing dysplasia and chronic atrophic gastric-carditis in population with high risk of gastric-cardia adenocarcinoma. Zhonghua Nei Ke Za Zhi, 44, 573-6.
- Xiao J, He X, Wang Z, et al (2014). Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer. Tumour Biol, 35, 1331-4. https://doi.org/10.1007/s13277-013-1177-1
- Ychou M, Duffour J, Kramar A, et al (2000). Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers, 16, 105-10. https://doi.org/10.1155/2000/595492
- Zheng S, Vuitton L, Sheyhidin I, et al (2010). Northwest China: a place to learn more on oesophageal cancer Part one: behavioural and environmental risk factors. Eur J Gastroenterol Hepatol, 22, 917-25. https://doi.org/10.1097/MEG.0b013e3283313d8b
- Zhang YH, Li Y, Chen C, et al (2009). Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy. Hepatogastroenterol, 56, 1750-4.
피인용 문헌
- Translational progress on tumor biomarkers vol.6, pp.6, 2015, https://doi.org/10.1111/1759-7714.12294
- CdSe/ZnS Quantum Dot-Labeled Lateral Flow Strips for Rapid and Quantitative Detection of Gastric Cancer Carbohydrate Antigen 72-4 vol.11, pp.1, 2016, https://doi.org/10.1186/s11671-016-1355-3
- Prognostic value of serum tumor abnormal protein in gastric cancer patients vol.5, pp.1, 2016, https://doi.org/10.3892/mco.2016.877